NASDAQ:TCRT Alaunos Therapeutics Q1 2025 Earnings Report $1.13 -0.02 (-1.74%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$1.14 +0.01 (+0.44%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alaunos Therapeutics EPS ResultsActual EPS-$0.67Consensus EPS -$4.50Beat/MissBeat by +$3.83One Year Ago EPSN/AAlaunos Therapeutics Revenue ResultsActual Revenue$0.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlaunos Therapeutics Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time12:30PM ETUpcoming EarningsAlaunos Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Alaunos Therapeutics Earnings HeadlinesAlaunos Therapeutics Announces New Registered Direct OfferingSeptember 22 at 5:11 PM | tipranks.comAlaunos Prices $1.12M Registered Direct OfferingSeptember 19, 2026 | rttnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Alaunos Therapeutics Stock Falls 17% After Public Offering AnnouncementSeptember 19, 2026 | rttnews.comAlaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rulesSeptember 18, 2026 | globenewswire.comWhy Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving PremarketSeptember 18, 2026 | benzinga.comSee More Alaunos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email. Email Address About Alaunos TherapeuticsAlaunos Therapeutics (NASDAQ:TCRT) was a clinical-stage biotechnology company focused on developing genetically engineered T-cell therapies for cancer. Its primary research centered on T-cell receptor (TCR) therapies designed to recognize cancer-associated antigens and target solid tumors, an area that has historically been challenging for cell therapy developers. The company’s technology portfolio included the Sleeping Beauty nonviral gene-transfer system, which was intended to introduce tumor-targeting TCRs into a patient’s T cells. Alaunos also pursued personalized therapies targeting tumor-specific mutations, commonly known as neoantigens, and evaluated its programs through collaborations and clinical research involving academic and medical institutions, including the National Cancer Institute. Alaunos was formerly known as Ziopharm Oncology and adopted its current name in 2022. The company was headquartered in Houston, Texas, and its programs were primarily directed toward patients with advanced cancers in the United States. Alaunos subsequently reduced operations and reassessed its development strategy, and publicly available information about its ongoing programs and leadership is limited.View Alaunos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
